Suppr超能文献

程序性死亡配体 1 表达和浸润淋巴细胞在配对切除的原发性和转移性非小细胞肺癌中的异质性。

Heterogeneity of programmed death-ligand 1 expression and infiltrating lymphocytes in paired resected primary and metastatic non-small cell lung cancer.

机构信息

Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, China.

Department of Pathology, Tianjin Medical University Cancer Institute and Hospital; National Clinical Research Center of Cancer; Key Laboratory of Cancer Prevention and Therapy, Tianjin; Tianjin's Clinical Research Center of Cancer, Tianjin, China.

出版信息

Mod Pathol. 2022 Feb;35(2):218-227. doi: 10.1038/s41379-021-00903-w. Epub 2021 Sep 7.

Abstract

Metastatic tumors (MTs) may show different characteristics of the immune microenvironment from primary tumors (PTs) in non-small cell lung cancer (NSCLC). The heterogeneity of immune markers in metastatic NSCLC and its associated factors has not been well demonstrated. In this study, 64 surgically resected specimens of paired PTs and MTs were obtained from 28 patients with NSCLC. Multiplex immunofluorescence (mIF; panel including programmed death-ligand 1 (PD-L1), Cytokeratin, CD8, and CD68) was performed on whole sections. The heterogeneity of the immune contexture of PD-L1 expression, infiltrating lymphocytes, and immune-to-tumor cell distances was quantified via digital image analysis. In a quantitative comparison of MTs and corresponding PTs, MTs showed higher PD-L1 expression levels, lower density of CD8+ cytotoxic T lymphocytes (CTLs), and longer spatial distance between CTLs and tumor cells. Subgroup analysis, which associated clinical factors, revealed that the heterogeneity of immune markers was more obvious in extrapulmonary, metachronous, and treated MTs, while fewer differences were observed in intrapulmonary, synchronous, and untreated MTs. In particular, MTs showed significantly higher PD-L1 expression and lower lymphocyte infiltration in metastatic NSCLC with EGFR mutations. Prognosis analysis showed that an increased density of CD8+ CTLs in MTs was associated with better overall survival (OS). Therefore, significant discrepancies in PD-L1 expression and lymphocyte infiltration in metastatic NSCLC are most likely associated with temporal heterogeneity with a history of anti-treatment and correlated with EGFR mutations. The detection of immune markers in re-obtained metastatic specimens may be required for immunotherapy prediction in these patients with metastatic NSCLC.

摘要

转移性肿瘤 (MTs) 可能与非小细胞肺癌 (NSCLC) 的原发性肿瘤 (PTs) 具有不同的免疫微环境特征。转移性 NSCLC 中免疫标志物的异质性及其相关因素尚未得到很好的证明。在这项研究中,从 28 名 NSCLC 患者中获得了 64 对手术切除的 PT 和 MT 标本。对全切片进行了多重免疫荧光(mIF;包括程序性死亡配体 1 (PD-L1)、细胞角蛋白、CD8 和 CD68)。通过数字图像分析量化了 PD-L1 表达、浸润淋巴细胞和免疫细胞与肿瘤细胞之间距离的免疫结构异质性。在 MT 和相应 PT 的定量比较中,MT 显示出更高的 PD-L1 表达水平、更低密度的 CD8+细胞毒性 T 淋巴细胞 (CTL) 和 CTL 与肿瘤细胞之间更长的空间距离。与临床因素相关的亚组分析表明,在肺外、同时性和治疗性 MT 中,免疫标志物的异质性更为明显,而在肺内、同时性和未治疗性 MT 中观察到的差异较少。特别是,在 EGFR 突变的转移性 NSCLC 中,MT 显示出明显更高的 PD-L1 表达和更低的淋巴细胞浸润。预后分析表明,MT 中 CD8+CTL 的密度增加与更好的总生存期 (OS) 相关。因此,转移性 NSCLC 中 PD-L1 表达和淋巴细胞浸润的显著差异很可能与具有抗治疗史的时间异质性相关,并与 EGFR 突变相关。在这些转移性 NSCLC 患者中,可能需要对重新获得的转移性标本中的免疫标志物进行检测,以预测免疫治疗效果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验